Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study.

Wilailak S, Vipupinyo C, Suraseranivong V, Chotivanich K, Kietpeerakool C, Tanapat Y, Therasakvichya S, Hamontri S, Linasmita V, Bunyapipat S, Chindavijak S, Ittiwisavakul K, Khemapech N, Suekwattana P, Thanapprapasr D, Lumbiganon P.

BJOG. 2012 May;119(6):672-7. doi: 10.1111/j.1471-0528.2012.03298.x.

2.

Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case--control study.

Lumbiganon P, Rugpao S, Phandhu-fung S, Laopaiboon M, Vudhikamraksa N, Werawatakul Y.

Br J Obstet Gynaecol. 1996 Sep;103(9):909-14.

PMID:
8813312
3.

Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.

Kaunitz AM.

J Reprod Med. 1996 May;41(5 Suppl):419-27. Review.

PMID:
8725705
5.

Bone density in women receiving depot medroxyprogesterone acetate for contraception.

Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR.

BMJ. 1991 Jul 6;303(6793):13-6. Erratum in: BMJ 1991 Jul 27;303(6796):220.

6.

Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary.

Lumbiganon P.

Contraception. 1994 Mar;49(3):203-9. Review.

PMID:
8200214
7.

Depo Provera. Position paper on clinical use, effectiveness and side effects.

Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M.

Br J Fam Plann. 1999 Jul;25(2):69-76. Review. Erratum in: Br J Fam Plann 2000 Jan;26(1):52-3.

PMID:
10454658
9.

Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica.

Oberle MW, Rosero-Bixby L, Irwin KL, Fortney JA, Lee NC, Whatley AS, Bonhomme MG.

Int J Epidemiol. 1988 Dec;17(4):718-23.

PMID:
2976059
10.

Bone mineral density in long-term depot medroxyprogesterone acetate acceptors.

Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K.

Contraception. 1997 Jul;56(1):1-3.

PMID:
9306024
12.

The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.

Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR.

Clin Endocrinol (Oxf). 1998 Nov;49(5):615-8.

PMID:
10197077
13.

Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study.

Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR.

Am J Epidemiol. 2002 Aug 15;156(4):363-73.

PMID:
12181107
15.

Long-term depot-medroxyprogesterone acetate and bone mineral density.

Tang OS, Tang G, Yip P, Li B, Fan S.

Contraception. 1999 Jan;59(1):25-9.

PMID:
10342083
16.

Bone density in long term users of depot medroxyprogesterone acetate.

Gbolade B, Ellis S, Murby B, Randall S, Kirkman R.

Br J Obstet Gynaecol. 1998 Jul;105(7):790-4.

PMID:
9692421
18.

Adolescent use of the monthly contraceptive injection.

Tuchman LK, Huppert JS, Huang B, Slap GB.

J Pediatr Adolesc Gynecol. 2005 Aug;18(4):255-60.

PMID:
16171729
19.

Bone mineral density, fracture, and vitamin D in adolescents and young women using depot medroxyprogesterone acetate.

Pitts SA, Feldman HA, Dorale A, Gordon CM.

J Pediatr Adolesc Gynecol. 2012 Feb;25(1):23-6. doi: 10.1016/j.jpag.2011.07.014. Epub 2011 Nov 12.

PMID:
22078997
20.

Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.

Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG.

Am J Obstet Gynecol. 1996 Aug;175(2):396-401.

PMID:
8765259

Supplemental Content

Support Center